Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Hims & Hers’

Hims & Hers Health: A Stock to Trade or Own?

HIMS achieved remarkable growth in 2024 but now faces challenges in 2025, raising the question of whether it suits traders better than long-term investors.

MarketBeat

Erectile Dysfunction Treatment Provider Donates $1 Million to Trump Inauguration

Hims & Hers is the latest US corporation to donate $1 million to President-elect Donald Trump's ever-growing inauguration fund.

Latin Times

4 Stocks That Crushed Analyst Estimates by More Than Double

Hims & Hers, Alcoa, Vicor, and Stride crushed earnings with massive EPS beats. See what’s driving their growth and future potential.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Stock Market Today: Indexes Fall As Chevron, Disney Shine; Will American Airlines Hit A Buy Zone? (Live Coverage)

These blue chips rallied hard while a few big winners in 2024 faltered. American Airlines is setting up.

Investors Business Daily

IBD 50's No. 2 Stock, Hims & Hers, Smashes Estimates On 'Robust' Obesity Trajectory

Hims stock jumped early Tuesday after the online pharmacy beat expectations, helped by Hims & Hers' weight-loss drug.

Investors Business Daily

Hims & Hers Shares Rallied 22% Over Two Days. Why That Move Is Now At Risk.

Hims stock rallied almost 22% over two days on enthusiasm after the FDA said it will allow compounded versions of Lilly's obesity drug.

Investors Business Daily

Is Hims & Hers Stock a Buy for GLP-1 Upside?

Hims & Hers is a digital health company that is firing on all cylinders, while improving its profit margins at a robust pace.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Hims & Hers’ surprise 85% Wegovy discount is latest step on a journey to make medicine less ‘paternalistic,’ exec says

The compounded weight loss drug starts at $199 per month.

Fortune

After Doubling in the Past 6 Months, Will Hims & Hers Health Stock Continue Higher?

Telehealth company Hims & Hers is trading near record highs after issuing strong guidance for the full year ahead. With the stock up nearly 145% in the last six months, how much more upside is left for HIMS?

Barchart

Subscription-based care moves beyond peddling birth control and helping with hair loss

Online, direct-to-consumer health care has grown well beyond its roots mostly treating hair loss and acne or selling birth control pills

The Independent UK

This is exactly how often you should be having sex to boost health and happiness, according to research

Your need-to-knows.

Marie Claire

Digital mental health companies draw scrutiny and growing concerns

When Pat Paulson’s son told her he was feeling anxious and depressed at college, Paulson went through her Blue Cross Blue Shield provider directory and started calling mental health therapists. No providers in the Wisconsin city where her son’s university is located had openings. So she bought a monthly subscription…

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.